Abstract:V600E BRAF have been identified as new promising targets for the design of novel anticancer agents. It is reported that the inhibitors based on 2,3-dihydroimidazo[4,5]pyridin-2-one scaffold and a meta -substituted middle ring exhibit potent inhibitory activities toward V600E BRAF. To investigate how their chemical structures relate to the inhibitory activities and to identify the key structural elements that are required in the rational design of potential drug candidates of this class, molecular docking simulations and three-dimensional quantitative structure–activity relationship (3D-QSAR) methods were performed. The bioactive conformation was explored by docking one potent compound 1 into the active site of BRAF in its DFG-out inactive conformation. The constructed CoMFA and CoMSIA models produced statistically significant results with the cross-validated correlation coefficients q 2 of 0.563 and 0.624, non-cross-validated correlation coefficients r 2 of 0.982 and 0.962, and predicted correction coefficients r pred 2 of 0.822 and 0.875, respectively. In addition, the CoMFA and CoMSIA models were used to guide the design of a series of new inhibitors of this class with predicted excellent activities. Thus, these models may be used as an efficient tool to predict the inhibitory activities and to guide the future rational design of 2,3-dihydroimidazo[4,5]pyridin-2-one derivatives with a meta substitution pattern as BRAF inhibitors with potent activities.

Quantitatives Structure-Activity Relationship and Modification of HIV Protease Inhibitors

Three dimensional quantitative structure-activity relationship of DATA analogues as HIV-1 reverse transcriptase inhibitors

Quantitative Structure-Activity Relationships of Hiv-1 Integrase Inhibitors of Dkas

Multi-target QSAR study in the analysis and design of HIV-1 inhibitors

Screening Novel HIV-1 Protease Inhibitors Based on the Substrate Envelope Hypothesis

Elucidating the Inhibiting Mode of AHPBA Derivatives Against HIV-1 Protease and Building Predictive 3D-QSAR Models

Proteochemometric Modeling Of The Bioactivity Spectra Of Hiv-1 Protease Inhibitors By Introducing Protein-Ligand Interaction Fingerprint

Evaluation of Novel HIV-1 Protease Inhibitors with DRV-resistance by Utilizing 3D-QSAR Molecular Docking and Molecular Dynamics Simulation

Modeling Studies of Peptide Inhibitors for the HIV Protease

Three Dimensional Quantitative Structure-activity Relationship of HEPT Analogues As HIV-1 Reverse Transcriptase Inhibitors

QSAR Studies on 1-Aryl-tetrahydroisoquinoline Analogs As Active Anti-HIV Agents Based on PSO-v-SVM

QSAR Study on Pyranones for Inhibitor of HIV Protease

Docking Field-Based QSAR and Pharmacophore Studies on the Substituted Pyrimidine Derivatives Targeting HIV-1 Reverse Transcriptase

QSAR Study of Carboxylic Acid Derivatives As HIV-1 Integrase Inhibitors

Applications of Genetic Algorithms on the Structure–activity Correlation Study of a Group of Non-Nucleoside HIV-1 Inhibitors

Activity prediction of hepatitis C virus NS5B polymerase inhibitors of pyridazinone derivatives

Quantitative Structure_Activity Relationship Studies of Nevirapine Derivatives Anti-HIV Drug using New Three-dimensional Structure Descriptors

Qsar Studies of Hept Derivatives As Anti-Hiv Drugs Using the Rasms Method

QSAR Studies of Anti-HIV Drug HEPT Using 3D-Hovaif

Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors Ⅱ 3D-QSAR Study on 6-(1-naphthylmethyl)substituted Thymines

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors